携带p.Ile1157Thr C3基因突变的非典型溶血性尿毒症综合征经血浆置换和依库珠单抗治疗成功:一例病例报告
本文报告一例16岁青少年,流感A感染后出现发热、关节痛、血尿、出血倾向及紫癜,实验室检查示严重血小板减少、高胆红素血症和急性肾损伤,外周血见裂红细胞。立即开始连续血液透析滤过和血浆输注,但出现少尿;ICU第3天开始血浆置换,但少尿、溶血和血小板减少持续;第7天开始静脉依库珠单抗治疗,症状恢复并成功脱离肾脏支持。血浆置换前ADAMTS13活性104.9%,粪便未检出产志贺毒素大肠埃希菌,基因分析发现C3 p.Ile1157Thr突变,确诊aHUS。目前依库珠单抗(1200 mg,隔周一次)维持治疗,无复发。作者认为,在管理感染继发血小板减少时,早期将aHUS纳入鉴别诊断在临床实践中很重要。
要点
- 16岁青少年流感A感染后出现发热、关节痛、血尿,随后发生出血倾向、紫癜、严重血小板减少、高胆红素血症和急性肾损伤,外周血见裂红细胞,应怀疑aHUS。
- 血浆置换前ADAMTS13活性104.9%,粪便未检出产志贺毒素大肠埃希菌,基因分析发现C3 p.Ile1157Thr突变,确诊aHUS。
- 连续血液透析滤过和血浆输注后仍少尿;ICU第3天开始血浆置换,但少尿、溶血和血小板减少持续;第7天开始静脉依库珠单抗后症状恢复并成功脱离肾脏支持。
- 患者目前依库珠单抗(1200 mg,隔周一次)维持治疗,无aHUS症状复发,溶血和急性肾损伤未再出现。
- 作者认为,在管理感染继发血小板减少时,早期将aHUS纳入鉴别诊断在临床实践中很重要。
适用人群与场景
- 16岁青少年,流感A感染后出现发热、关节痛、血尿,随后发生出血倾向、紫癜、严重血小板减少、高胆红素血症和急性肾损伤。
诊断标准与关键阈值
- 血浆置换前ADAMTS13活性104.9%,粪便未检出产志贺毒素大肠埃希菌,基因分析发现C3 p.Ile1157Thr突变,确诊aHUS。
处置流程与药物剂量
- 立即开始连续血液透析滤过和血浆输注。
- ICU第3天开始血浆置换。
- 第7天开始静脉依库珠单抗治疗。
- 目前依库珠单抗维持治疗:1200 mg,隔周一次。
红旗征与不能漏的情况
- 出血倾向和紫癜( extremities and trunk)出现后转至千叶大学医院。
- 严重溶血导致天冬氨酸氨基转移酶、乳酸脱氢酶和钾无法测定。
- 少尿在连续血液透析滤过和血浆输注后仍出现,血浆置换后少尿、溶血和血小板减少持续。
研究设计与关键结果
- 病例报告:1例16岁青少年,流感A感染后发生aHUS,携带C3 p.Ile1157Thr突变;连续血液透析滤过和血浆输注后仍少尿,血浆置换后少尿、溶血和血小板减少持续,依库珠单抗治疗后症状恢复并成功脱离肾脏支持,维持治疗(1200 mg,隔周一次)无复发。
证据类型、等级与局限
- 证据类型:病例报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在管理感染继发血小板减少时,早期将aHUS纳入鉴别诊断在临床实践中很重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To describe a case of atypical hemolytic uremic syndrome induced by influenza A infection with the p.Ile1157Thr C3 mutation.
DATA SOURCES: Clinical observations of a patient.
STUDY SELECTION: Case reports.
DATA EXTRACTION: Data extracted from medical records, after patient's consent.
DATA SYNTHESIS: Four days prior to presentation to our hospital, a 16-year-old adolescent had a fever and arthralgia with hematuria. He was found to be positive for type A influenza and prescribed oseltamivir and acetaminophen by a primary-care physician. A bleeding tendency and purpura in the extremities and on the trunk developed; therefore, he was transferred to Chiba University Hospital. Hematology revealed severe thrombocytopenia, hyperbilirubinemia, and acute kidney injury. Aspartate aminotransferase, lactate dehydrogenase, and potassium could not be determined because of severe hemolysis. Highly elevated blood urea nitrogen and creatinine levels indicated acute kidney injury. A platelet count of 24,000/μL indicated thrombocytopenia, with low hemoglobin level. Peripheral blood profiling identified schistocytes. Continuous hemodiafiltration and plasma infusion were initiated immediately; however, he became oliguric. Plasma exchange was initiated on ICU day 3, but decreased urine output, hemolysis, and thrombocytopenia persisted. IV eculizumab therapy was initiated on day 7 and resulted in recovery of these symptoms and also successful discontinuation of renal support. The patient showed a stable condition without recurrence of hemolytic findings and acute kidney injury and is currently on maintenance therapy of eculizumab (1,200 mg, every other week) without any relapse of atypical hemolytic uremic syndrome symptoms. A plasma sample collected prior to initiation of plasma exchange showed an disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13 activity level of 104.9%. The absence of both Shiga toxin-producing Escherichia coli in feces led to suspicion of atypical hemolytic uremic syndrome. Subsequent genetic analysis identified a mutation in C3 (p.Ile1157Thr), confirming the diagnosis of atypical hemolytic uremic syndrome.
CONCLUSIONS: Although managing thrombocytopenia secondary to infection, inclusion of atypical hemolytic uremic syndrome in the differential diagnosis at an early stage is important in clinical practice.
参考来源
- Saito D, Watanabe E, Ashida A, et al. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor. 2019. PMID: 32166254. doi:10.1097/CCE.0000000000000008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。